FMP
Outlook Therapeutics, Inc.
OTLK
NASDAQ
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
5.83 USD
0.0854 (1.47%)
About
ceo
Mr. C. Russell Trenary III
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, In...
CIK
0001649989
ISIN
US69012T3059
CUSIP
69012T206
Address
Building F
Phone
609 619 3990
Country
US
Employee
24
IPO Date
Jun 14, 2016
OTLK Financial Summary
CIK
0001649989
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
69012T206
ISIN
US69012T3059
Country
US
Price
5.83
Beta
0.63
Volume Avg.
244.55k
Market Cap
137.8M
Shares
-
52-Week
4.61-13.32
DCF
-0.97
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.99
P/B
-
Website
https://www.outlooktherapeutics.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest OTLK News
It looks like there's no news available.
